2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2240

Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate: A Study Using Large Intergrated National Health Network

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2288

Effectiveness of Dry Needling and Exercise in Dizziness Caused By Cervical Myofascial Pain Syndrome

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2237

Effects of Coffee Consumption on Serum Uric Acid. a Systematic Review and Meta-Analysis

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2355

Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2489

Effects of Two Interventions on Rheumatologists Adherence to Optimal Care Recommendations in Rheumatoid Arthritis: A Combined before/after and Randomized Controlled Trial

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2352

Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2428

Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2363

Efficacy and Safety of Adrenocorticotropic Hormone Gel (Acthar Gel ®) in Refractory Dermatomyositis or Polymyositis

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2422

Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2350

Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2760

Efficacy and Safety of Sarilumab Plus MTX in Subgroups of Patients with Rheumatoid Arthritis in a Phase 3 Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2742

Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2856

Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylarthritis As Well As Peripheral Arthritis: Results from 2 Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2962

Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2770

Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].